TRDMT1-mediated RNA C-5 methylation as a novel target in anticancer therapy
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2023
DOI: 10.1016/j.bbcan.2023.188964 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023. Verfasst von Anna Lewinska und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biotechnology, College of Natural Sciences, University of Rzeszow, Pigonia 1, 35-310 Rzeszow, Poland. Electronic address: alewinska@ur.e…. Hauptthemen laut MEDLINE: DNA (Cytosine-5-)-Methyltransferases, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki.
Abstract (Originalsprache)
Affected landscape of RNA modifications is frequently observed in different cancer cells that can be associated with the development of cancer cell phenotypic traits such as sustained proliferation, migration and invasion, apoptosis resistance and metabolic reprograming. DNMT2/TRDMT1 5-methylcytosine methyltransferase, initially classified as DNA methyltransferase, can methylate both tRNA and mRNA promoting tRNA stability and proper protein synthesis, and orchestrating DNA damage response (DDR) and DNA stability, respectively. TRDMT1 is associated with cancer progression as its levels can be elevated and its mutations can be observed in a number of cancer types. TRDMT1 gene knockout (KO) can sensitize cancer cells of different origin to radiotherapy and chemotherapy. In the present review paper, based on literature data, the physiological and pathophysiological roles of TRDMT1 in different biological systems are described with the emphasis on human normal and cancer cells. Potential TRDMT1 substrates, inhibitors and regulatory mechanisms of catalytic activity and cellular localization are also presented and evaluated. TRDMT1 as a novel promising target in anticancer therapy is proposed and discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biotechnology, College of Natural Sciences, University of Rzeszow, Pigonia 1, 35-310 Rzeszow, Poland. Electronic address: alewinska@ur.edu.pl.
- Institute of Biotechnology, College of Natural Sciences, University of Rzeszow, Pigonia 1, 35-310 Rzeszow, Poland.
- Institute of Biotechnology, College of Natural Sciences, University of Rzeszow, Pigonia 1, 35-310 Rzeszow, Poland. Electronic address: mwnuk@ur.edu.pl.
Förderung
- Narodowe Centrum Nauki
Zitieren
APA
Lewinska, A., Adamczyk-Grochala, J., & Wnuk, M. (2023). TRDMT1-mediated RNA C-5 methylation as a novel target in anticancer therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2023.188964
Vancouver
Lewinska A, Adamczyk-Grochala J, Wnuk M. TRDMT1-mediated RNA C-5 methylation as a novel target in anticancer therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023. doi:10.1016/j.bbcan.2023.188964
BibTeX
@article{Lewinska2023,
author = {Lewinska, Anna and Adamczyk-Grochala, Jagoda and Wnuk, Maciej},
title = {TRDMT1-mediated RNA C-5 methylation as a novel target in anticancer therapy},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2023},
doi = {10.1016/j.bbcan.2023.188964}
}
EUVIMED